IRulya Therapeutics (IRLA) Stock Analysis
NASDAQHealthcareBiotechnology
Track IRLA in your portfolio for free · Portfolio tracker
What IRulya Therapeutics does
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Key metrics
ETFs linked to IRLA
Broad-market and Healthcare sector ETFs an investor holding IRulya Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how IRLA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze IRLA in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for IRulya Therapeutics?
- IRulya Therapeutics trades under the ticker IRLA on NASDAQ.
- Which exchange is IRLA listed on?
- IRLA is listed on NASDAQ.
- What sector does IRulya Therapeutics operate in?
- IRulya Therapeutics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze IRLA in a portfolio?
- PortView shows IRLA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.